Clinical Takeaway
Cannabinoid-based treatments, including CBD-rich preparations, have shown preliminary benefits for certain autism-related symptoms such as irritability, hyperactivity, and sleep difficulties in clinical trial data. The evidence base remains limited in size and methodological rigor, so these findings should be interpreted cautiously. Patients and caregivers interested in cannabis therapies for autism should consult with a knowledgeable clinician to weigh individual risks and potential benefits.
#13 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
This systematic review synthesizes evidence from randomized controlled trials on cannabis derivatives for autism spectrum disorder, addressing a significant clinical gap given the lack of FDA-approved pharmacological treatments for core autistic symptoms and the growing patient interest in cannabis-based interventions. The structured evaluation of efficacy and safety data provides clinicians with an evidence-based framework for counseling patients and families considering cannabis therapies, particularly for behavioral and emotional dysregulation in autism. Given the limited pharmacological options for autism’s core features and the variability in real-world cannabis use among this population, this review offers critical guidance for clinical decision-making and identifies priorities for future rigorous research.
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
🧠 While this systematic review identifies promising signals for cannabis derivatives in autism spectrum disorder, clinicians should note that the evidence base remains limited and heterogeneous, with most studies examining CBD or CBD-dominant formulations rather than whole-plant cannabis. Critical confounders include variability in dosing regimens, duration of treatment, patient age ranges, and outcome measures across trials, which complicate direct comparison and generalizability to individual patients. The mechanism by which cannabinoids may improve social communication, behavioral rigidity, or emotional regulation in autism remains incompletely understood, and long-term safety data in this population are sparse. Given these caveats, cannabis-based treatments for autism may warrant consideration in carefully selected patients with refractory symptoms or comorbidities like anxiety or sleep disturbance, but only after conventional interventions have been optimized and with clear documentation of baseline functioning and defined therapeutic endpoints.